// App-Quantinova.ai

POS0467 (2022) : DERSIMELAGON, A NOVEL ORAL MELANOCORTIN 1 RECEPTOR AGONIST, DEMONSTRATES DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS

Researchers

Presenter

  • M. Kondo

Principal Investigators

  • T. Suzuki

  • Y. Kawano

  • S. Kojima

  • M. Miyashiro

  • A. Matsumoto

  • G. Kania

  • P. Blyszczuk

  • R. Ross

  • P. Mulipa

  • F. Del Galdo

  • Y. Zhang

  • J. H. W. Distler

Medical Centers

  • Mitsubishi Tanabe Pharma Corporation, Research Unit/Immunology & Inflammation, Souyaku Innovative Research Division, Yokohama, Japan

  • Mitsubishi Tanabe Pharma Corporation, Discovery Technology Laboratories, Souyaku Innovative Research Division, Yokohama, Japan

  • University Hospital Zurich, Center of Experimental Rheumatology, Department of Rheumatology, Schlieren, Switzerland

  • University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, Leeds, United Kingdom

  • Friedrich Alexander University Erlangen-Nuremberg and Universitaetsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany

Locations

  • Japan

  • Switzerland

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Scleroderma

Biomarkers

  • N/A

Drug/Treatment

  • Bleomycin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved